Fabino Enterprises Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Fabino Enterprises Ltd is ₹ 20.31 as of 27 Apr 15:30 . The P/E Ratio of Fabino Enterprises Ltd is 600 as of March 2023 .The P/E Ratio of Vaishali Pharma Ltd is 0 as of March 2023 . The Market Cap of Fabino Enterprises Ltd is ₹ 6.3 crore as of March 2023 .The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of March 2023 . The Revenue of Fabino Enterprises Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Fabino Enterprises Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Fabino Enterprises Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Fabino Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Fabino Enterprises Ltd

Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain.
The Company was incorporated as 'Fabino Life Sciences Private Limited' on October 27, 2011 with the Registrar of Companies, Delhi and Haryana.
Subsequently, the Company got converted to Public Limited Company and the name of Company was changed to 'Fabino Life Sciences Limited'.
A fresh Certificate of Incorporation was issued on March 21, 2015 by the Registrar of Companies, Delhi. The Company operate in the business of manufacturing, marketing of pharmaceutical, allopathic, herbal, veterinary, and other consumer products like, packing, trading, etc.
The core business is marketing of pharmaceutical formulation & products in domestic market through its own distribution network and sales force under own brand name, getting Ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Fabino Enterprises Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Fabino Enterprises Ltd or Vaishali Pharma Ltd?

Market cap of Fabino Enterprises Ltd is 4 Cr while Market cap of Vaishali Pharma Ltd is 99 Cr

What are the key factors driving the stock performance of Fabino Enterprises Ltd and Vaishali Pharma Ltd?

The stock performance of Fabino Enterprises Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fabino Enterprises Ltd and Vaishali Pharma Ltd?

As of May 3, 2026, the Fabino Enterprises Ltd stock price is INR ₹20.31. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.61.

How do dividend payouts of Fabino Enterprises Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Fabino Enterprises Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.